|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | PD-1/PD-L1 inhibitor 2 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||||||||||
| 化学式 | C25H29N3O3 |
||||||||||||||
| 分子量 | 419.52 | CAS No. | 1675203-84-5 | ||||||||||||
| Solubility (25°C)* | 体外 | DMSO | 83 mg/mL (197.84 mM) | ||||||||||||
| Ethanol | 83 mg/mL (197.84 mM) | ||||||||||||||
| Water | Insoluble | ||||||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||||||
| 製品説明 | BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM. |
|---|---|
| in vitro | BMS-202 inhibits PD-1/PD-L1 binding in SCC-3 and Jurkat cells with IC50 of 15 μM and 10 μM, respectively. |
| in vivo | BMS-202 treatment shows a clear antitumor effect compared with the controls, in humanized MHC- dKO NOG mice. |
| 細胞アッセイ | 細胞株 | SCC-3 and Jurkat cells |
|---|---|---|
| 濃度 | IC50 of 15 μM and 10 μM | |
| 反応時間 | 4 days | |
| 実験の流れ | Cells were treated with various concentrations of drug for 4 days. |
|
| 動物実験 | 動物モデル | NOG-dKO mice |
| 投薬量 | 20 mg/kg | |
| 投与方法 | i.p. |
|
| Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer [ Front Immunol, 2025, 16:1529710] | PubMed: 40109332 |
| Metabolic profiling of glioblastoma and identification of G0S2 as a metabolic target [ Front Oncol, 2025, 15:1572040] | PubMed: 40519301 |
| Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model [ Sci Rep, 2025, 15(1):26918] | PubMed: 40707559 |
| In Vivo Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models [ In Vivo, 2025, 39(1):80-95] | PubMed: 39740910 |
| Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade [ Phytomedicine, 2024, 125:155370] | PubMed: 38266440 |
| Development and In Vivo Evaluation of Small-Molecule Ligands for Positron Emission Tomography of Immune Checkpoint Modulation Targeting Programmed Cell Death 1 Ligand 1 [ J Med Chem, 2024, 67(5):4036-4062] | PubMed: 38442487 |
| Isolation and Total Synthesis of PM170453, a New Cyclic Depsipeptide Isolated from Lyngbya sp [ Mar Drugs, 2024, 22(7)303] | PubMed: 39057411 |
| Theoretical and experimental studies on the interaction of biphenyl ligands with human and murine PD-L1: Up-to-date clues for drug design [ Comput Struct Biotechnol J, 2023, 21:3355-3368] | PubMed: 37384351 |
| Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency [ Int J Mol Sci, 2023, 24(6)5535] | PubMed: 36982608 |
| Turning a Tumor Microenvironment Pitfall into Opportunity: Discovery of Benzamidoxime as PD-L1 Ligand with pH-Dependent Potency [ Int J Mol Sci, 2023, 24(6)5535] | PubMed: 36982608 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。